Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database

摘要: 4010 Background: Prior studies suggested that older and younger pts with colon cancer receive similar benefit from IV fluoropyrimidine (FU) adjuvant (adj) therapy (rx). Combination and/or oral FU rx are increasingly given as adj rx. We sought to determine the impact of age <70 v ≥70 yrs on recurrence mortality these newer options. Methods: used data 10,499 2,170 in 6 phase III trials comparing combinations irinotecan, oxaliplatin or (capecitabine UFT/LV) stage II/III ACCENT database. Endpoints were overall survival (OS; time death), disease-free (DFS; (TTR; censoring at last follow-up). Cox models stratified by adjusted for gender stage; interaction testing was explore differential age. Results: Approximately 75% had disease (74% age<70, 77% age≥70). OS, D...